NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · SEPN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Septerna Inc’s quoted price sits in the upper half of its reported 52-week range, 11.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Septerna Inc’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.42. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Septerna Inc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 15, 2025 |
| -$0.49-28.95% vs estimate |
| $219.00K-99.27% vs estimate |
| Q4 2024 | Mar 27, 2025 | -$0.64+7.25% vs estimate | $212.00K |
|---|
| Q3 2024 | Nov 21, 2024 | -$8.40-912.05% vs estimate | $176.00K |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $49.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$54.54+$0.38 (+0.7%)
MBX Biosciences, Inc. Common Stock’s quoted price sits in the upper half of its reported 52-week range, 24.92% below the high.
$31.93+$0.20 (+0.63%)
Maze Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.48% below the high.
$13.41-$0.01 (-0.07%)
Kailera Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.5% below the high.
$21.94+$0.46 (+2.14%)
Structure Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.88% below the high.
$26.38+$0.66 (+2.57%)
vTv Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.05% below the high.
$0.62-$0.02 (-3.84%)
Biomea Fusion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.2% below the high.
